(Sharecast News) - Avacta Therapeutics shares were rising on Tuesday, after new data presented at the American Association for Cancer Research (AACR) 2026 annual meeting highlighted the favourable profile of its AVA6103 candidate and the broader potential of its 'preCISION' tumour-targeted delivery platform.
The AIM-traded clinical-stage group presented updated preclinical and...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE